Company / PP&E (Net)
BIOCRYST PHARMACEUTICALS INC PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$8.8M
FY2025
5-year range
$7.8M / $8.8M
FY2021-FY2025
Trend
+12.9%
vs FY2024
Sector context
#97 of 193
Health Care
What the data says
At $9M, BIOCRYST PHARMACEUTICALS INC's pp&e (net) ranks #97 of 193 in the Health Care sector. PP&E (Net) returned to growth in FY2025 after 3 years of decline, reaching $9M.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of +4.3%.
Improved from $8M to $9M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +0.6%
- 5-Year CAGR
- +4.3%
- 10-Year CAGR
- -
Sector benchmark
#97 of 193 in Health CareTop 50% of 193This company $8.8M Sector average $777.6M
▼
-98.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.3%, indicating consistent growth.
- In FY2025, pp&e (net) increased 12.9% year-over-year.
- Ranks #97 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.8M | +12.9% |
| FY2024 | $7.8M | -1.7% |
| FY2023 | $7.9M | -8.2% |
| FY2022 | $8.6M | -1.1% |
| FY2021 | $8.7M | +22.5% |
| FY2020 | $7.1M | -3.2% |
| FY2019 | $7.3M | -19.6% |
| FY2018 | $9.1M | -4.3% |
| FY2017 | $9.5M | -3.8% |
| FY2016 | $9.9M | +92.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026